Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Feasibility Study of FMT for Pediatric SIBO
NCT05967871Phase 1Recruiting
- Sponsor
- McMaster Children's Hospital
- Start
- Mar 2024
- Primary completion
- Dec 2026
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fecal microbiome transplant in small intestinal bacterial overgrowth (SIBO), sponsored by McMaster Children's Hospital. Primary endpoints: Change in Clinical Symptoms at 8 weeks, Rate of Clinical Remission at 8 weeks and 4 more. Started Mar 2024; status: recruiting.
02
Drugs
fecal microbiome transplant
03
Conditions
small intestinal bacterial overgrowth (SIBO)
Beyond the preview
Go deeper on NCT05967871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05967871.